- Home
- REBN vs NERV Comparison
REBN vs NERV Comparison
Compare REBN & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- NERV
- Stock Information
- Founded
- REBN 2015
- NERV 2007
- Country
- REBN United States
- NERV United States
- Employees
- REBN N/A
- NERV N/A
- Industry
- REBN Restaurants
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- NERV Health Care
- Exchange
- REBN Nasdaq
- NERV Nasdaq
- Market Cap
- REBN 13.3M
- NERV 14.6M
- IPO Year
- REBN 2022
- NERV 2014
- Fundamental
- Price
- REBN $2.11
- NERV $4.78
- Analyst Decision
- REBN
- NERV Hold
- Analyst Count
- REBN 0
- NERV 1
- Target Price
- REBN N/A
- NERV $5.00
- AVG Volume (30 Days)
- REBN 57.7K
- NERV 9.3M
- Earning Date
- REBN 11-18-2025
- NERV 11-05-2025
- Dividend Yield
- REBN N/A
- NERV N/A
- EPS Growth
- REBN N/A
- NERV N/A
- EPS
- REBN N/A
- NERV 1.48
- Revenue
- REBN $6,565,623.00
- NERV N/A
- Revenue This Year
- REBN $335.98
- NERV N/A
- Revenue Next Year
- REBN N/A
- NERV N/A
- P/E Ratio
- REBN N/A
- NERV $3.06
- Revenue Growth
- REBN 14.03
- NERV N/A
- 52 Week Low
- REBN $1.03
- NERV $1.15
- 52 Week High
- REBN $8.30
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- REBN 36.65
- NERV 63.84
- Support Level
- REBN $2.14
- NERV $4.27
- Resistance Level
- REBN $2.37
- NERV $12.46
- Average True Range (ATR)
- REBN 0.14
- NERV 0.86
- MACD
- REBN 0.00
- NERV 0.16
- Stochastic Oscillator
- REBN 15.31
- NERV 24.84
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.